Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06915792 · ClinicalTrials.gov registry record · Phase 4
PEACE Trial: Postpartum Evaluation of Antihypertensive Cessation and Efficacy
A Phase 4 study, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 110
- Enrollment target
NCT06915792: Recruiting Phase 4 study, sponsored by University of California, Los Angeles.
NCT06915792 is a Phase 4 study that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 110 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06915792, a Phase 4 study, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 110 participants
- Enrollment target
Study Summary
This randomized controlled trial compares two common medications, labetalol and extended-release nifedipine, to determine which is more effective at managing postpartum high blood pressure. We hypothesize that extended-release nifedipine will better control blood pressure and reduce the need for continued medication beyond six weeks postpartum. The study will enroll 110 postpartum participants, randomly assigning them to one of the two medications, with remote blood pressure monitoring to evaluate treatment effectiveness and inform postpartum hypertension management.
Primary Outcome
The proportion of participants who continue to require antihypertensive medication beyond 6 weeks postpartum
Interventions
- DRUG Labetalol
- DRUG Nifedipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2025-06-01 |
| Est. Completion | 2027-10-31 |
| Phase | Phase 4 |
What NCT06915792 shows while recruiting
NCT06915792 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 2 interventions - of which Labetalol is the first listed.
NCT06915792 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06915792 about?
NCT06915792 is a clinical study titled "PEACE Trial: Postpartum Evaluation of Antihypertensive Cessation and Efficacy". This randomized controlled trial compares two common medications, labetalol and extended-release nifedipine, to determine which is more effective at managing postpartum high blood pressure. We hypothesize that extended-release nifedipine will better control blood pressure and reduce the need for con...
What is the current status of trial NCT06915792?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 110 participants. The study started on 2025-06-01. Estimated completion is 2027-10-31.
What interventions are being tested in trial NCT06915792?
The interventions under investigation include: Labetalol (DRUG), Nifedipine (DRUG).
Who is sponsoring clinical trial NCT06915792?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06915792's enrollment target sits among peer trials
110 727th of 2000 higher than 1,264 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI